Burns Matteson Capital Management LLC Takes Position in Bioventus Inc. (NYSE:BVS)

Burns Matteson Capital Management LLC purchased a new position in shares of Bioventus Inc. (NYSE:BVS) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 11,629 shares of the company’s stock, valued at approximately $67,000.

A number of other institutional investors have also added to or reduced their stakes in BVS. LSV Asset Management bought a new position in shares of Bioventus during the 1st quarter worth approximately $1,170,000. Bailard Inc. bought a new stake in Bioventus during the fourth quarter worth $307,000. Lazard Asset Management LLC purchased a new position in Bioventus in the first quarter worth $40,000. Quadrature Capital Ltd bought a new position in Bioventus in the 4th quarter valued at $85,000. Finally, GSG Advisors LLC grew its stake in Bioventus by 55.8% in the 1st quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock valued at $133,000 after purchasing an additional 9,500 shares during the period. 62.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group lifted their target price on Bioventus from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th.

Insiders Place Their Bets

In other Bioventus news, SVP Anthony D’adamio sold 5,904 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $5.57, for a total value of $32,885.28. Following the sale, the senior vice president now owns 95,576 shares of the company’s stock, valued at approximately $532,358.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Bioventus news, SVP Anthony D’adamio sold 5,904 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $5.57, for a total value of $32,885.28. Following the completion of the transaction, the senior vice president now owns 95,576 shares of the company’s stock, valued at approximately $532,358.32. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Mark Leonard Singleton sold 13,753 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $5.84, for a total value of $80,317.52. Following the completion of the transaction, the chief financial officer now directly owns 63,114 shares in the company, valued at approximately $368,585.76. The disclosure for this sale can be found here. Insiders have sold 40,184 shares of company stock worth $230,591 in the last three months. 32.90% of the stock is currently owned by corporate insiders.

Bioventus Stock Performance

Shares of BVS stock traded up $1.83 during trading on Tuesday, reaching $8.09. 1,192,419 shares of the company’s stock traded hands, compared to its average volume of 313,374. The firm’s 50-day moving average is $6.53 and its 200 day moving average is $5.52. The company has a market capitalization of $640.45 million, a P/E ratio of -23.11 and a beta of 0.84. Bioventus Inc. has a 1 year low of $2.82 and a 1 year high of $8.12. The company has a current ratio of 1.53, a quick ratio of 0.97 and a debt-to-equity ratio of 1.63.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.12. The firm had revenue of $129.46 million during the quarter, compared to analyst estimates of $115.51 million. Bioventus had a positive return on equity of 11.91% and a negative net margin of 4.14%. Equities research analysts expect that Bioventus Inc. will post 0.27 EPS for the current year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.